UK pharma major GSK has appointed Sanjay Gurunathan as senior vice president and global head vaccines and infectious disease ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

Calcium+Company, a 2025 MM+M Agency 100 honoree, named Susan Goldstein as an EVP who has joined the Protein team. Bobby ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval of Nucala for chronic obstructive pulmonary disease (COPD) and a ...

On GSK's media call earlier this month, Miels noted that the company plans to “essentially keep the same pricing structure that we already have” with Nucala, which currently costs around ...

British drugmaker GSK is preparing for potential new U.S. tariffs on its medicines and can handle the challenge, the company’s leader said Wednesday. “I would say we’ve been preparing ...

After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan ...

On 20 May 2025 at the American Thoracic Society (ATS) International Conference in San Francisco, a poster presentation by GlaxoSmithKline (GSK) provided insight into the therapeutic benefit of ...

GSK said combinations of its blood-cancer treatment, Blenrep, have been approved by Japan’s Ministry of Health, and that it expects more approvals through the year. The U.K. pharma company said ...